


Claims

1. Compound of general formula (i)



(I)

in the form of racemic, enantiomeric mixture or any combination of these forms,

in which


5 R_1 represents a hydrogen atom or an alkyl, cycloalkyl, cycloalkylalkyl radical, or also one of the aryl or aralkyl radicals, the aromatic ring of which is optionally substituted from once to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical;

R_2 represents a hydrogen atom or an alkyl radical;

R_3 represents a hydrogen atom or an alkyl or aralkyl radical;

10 X represents a bond or a linear or branched alkylene radical containing from 1 to 5 carbon atoms;

Y represents a hydrogen atom, a cycloalkyl radical, an NR_4R_5 , OR_{14} or SR_{15} radical or a



15 radical, or also Y represents an aryl radical optionally substituted from once to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical;

A represents a bond or the phenylene radical;

B and B' are chosen independently from an alkyl radical, a cycloalkyl radical, an NR₆R₇ or SR₈ radical, a carbocyclic aryl radical or a heterocyclic aryl radical with 5 or 6 members containing from 1 to 4 heteroatoms chosen from O, S and N, said carbocyclic and heterocyclic aryl radicals being optionally substituted by one to three groups chosen independently from the alkyl, alkenyl or alkoxy radicals,

R₄ represents a hydrogen atom or an alkyl, cycloalkyl, cycloalkylalkyl, -C(O)R₉, -C(O)OR₉, -C(O)NHR₉ or -SO₂R₉ radical, or also one of the aryl or aralkyl radicals the aromatic ring of which is optionally substituted from once to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical, or R₄ represents a *bis*-phenylalkyl radical,

R₅ represents a hydrogen atom or an alkyl, aryl or aralkyl radical, or also R₄ and R₅ form with the nitrogen atom which carries them a non-aromatic heterocycle with five to seven members containing from 1 to 2 heteroatoms, the elements for completing the heterocycle being chosen independently from a group comprising -CHR₁₀-, -NR₁₁-, -O- and -S-;

R₆ and R₇ represent independently a hydrogen atom or an alkyl, alkenyl or alkynyl radical, or R₆ represents a nitro radical and R₇ represents a hydrogen atom, or also R₆ and R₇ form with the nitrogen atom which carries them a non-aromatic heterocycle with five to six members, the elements for completing the heterocycle being chosen independently from a group comprising -CH₂-, -NR₁₂-, -O- and -S-;

R₈ represents a linear or branched alkyl radical having 1 to 6 carbon atoms optionally substituted from once to 3 times by one or more substituents chosen independently from a halogen atom and the -OH, amino, cyano and aryl radicals;

R₉ represents an alkyl, haloalkyl, cycloalkyl or cycloalkylalkyl radical, or also one of the carbocyclic or heterocyclic aralkyl or aryl radicals the aromatic ring of which is optionally substituted from once to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical;

R₁₀ represents a hydrogen atom or an alkyl or aryl radical optionally substituted from once to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,

R_{11} represents a hydrogen atom, an alkyl radical, a cycloalkyl radical, a cycloalkylalkyl radical, a $-C(O)R_{13}$ radical, a $-C(O)OR_{13}$ radical, an $-SO_2R_{13}$ radical, a $-C(O)NHR_{13}$ radical, or also one of the aryl or aralkyl radicals, the aromatic ring of which is optionally substituted from once to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical;

R_{12} represents a hydrogen atom or an alkyl radical;

R_{13} represents an alkyl radical, a haloalkyl radical or also one of the carbocyclic or heterocyclic aralkyl or aryl radicals the aromatic ring of which is optionally substituted from once to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical;

R_{14} represents an alkyl radical, the phenyl radical or an aralkyl radical; and finally

R_{15} represents an alkyl radical, the phenyl radical or an aralkyl radical;

it being understood:


- that an alkyl or alkoxy radical, unless otherwise specified, is linear or branched and contains from 1 to 12 carbon atoms;
- that an alkenyl or alkynyl radical, unless otherwise specified, is linear or branched and contains from 2 to 6 carbon atoms;
- that a cycloalkyl radical, unless otherwise specified, comprises from 3 to 7 carbon atoms;

or a salt of a compound of general formula (I).

2. Compound of general formula (I) according to claim 1, characterized in that X represents a bond or a linear or branched alkylene radical containing from 1 to 5 carbon atoms and Y represents an NR_4R_5 radical;

or a salt of this compound.

3. Compound of general formula (I) according to claim 1, characterized in that X represents a bond or a linear or branched alkylene radical containing from 1 to 5 carbon atoms and Y represents a



radical;

or a salt of this compound.

4. Compound of general formula **(I)** according to claim 1, characterized in that X represents a bond or a linear or branched alkylene radical containing from 1 to 5 carbon atoms and Y represents a cycloalkyl radical or an aryl radical optionally substituted from once to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical;

or a salt of this compound.

5. Compound of general formula **(I)** according to claim 1, characterized in that X represents a bond and Y represents a hydrogen atom whilst at least one of R₁ and R₂ represents a radical chosen from the alkyl, cycloalkyl or cycloalkylalkyl radicals;

or a salt of this compound.

6. Compound of general formula **(I)** according to claim 1, characterized in that it is chosen from the following compounds:

- butyl-2-[4-(4-{{[(1Z)-amino(thien-2-yl)methylene]-amino}}phenyl)-1H-imidazol-2-yl]ethylcarbamate;
- butyl-2-[4-(3-{{[(1E)-amino(thien-2-yl)methylene]-amino}}phenyl)-1H-imidazol-2-yl]ethylcarbamate;
- butyl-2-[4-(4'-{{[(1Z)-amino(thien-2-yl)methylene]amino}}-1,1'-biphenyl-4-yl)-1H-imidazol-2-yl]ethylcarbamate;
- N'-(4-{2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl}phenyl)thiophene-2-carboximidamide;
- N'-(4-{2-[2-(cyclohexylamino)ethyl]-1H-imidazol-4-yl}phenyl)thiophene-2-carboximidamide;
- N'-(3-{2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl}phenyl)thiophene-2-carboximidamide;
- N'-[4-(2-{{cyclohexyl(methyl)amino}methyl}-1H-imidazol-4-yl)phenyl]thiophene-2-carboximidamide;
- N'-(4-{2-{{dibenzylamino}methyl}-1H-imidazol-4-yl}phenyl)thiophene-2-carboximidamide;
- N'-(4-{2-[(benzylamino)methyl]-1H-imidazol-4-yl}phenyl)thiophene-2-carboximidamide;
- N'-(3-[2-(aminomethyl)-1H-imidazol-4-yl]phenyl)thiophene-2-carboximidamide;

- *N'*-{3-[2-({[(1*E*)-amino(thien-2-yl)methylene]-amino}methyl)-1*H*-imidazol-4-yl]phenyl}thiophene-2-carboximidamide;
- *N'*-{4-[2-({[(1*E*)-amino(thien-2-yl)methylene]-amino}methyl)-1*H*-imidazol-4-yl]phenyl}thiophene-2-carboximidamide;
- 5 - *N*-{3-[2-(2-cyclohexylethyl)-1*H*-imidazol-4-yl]phenyl}thiophene-2-carboximidamide;
- *N'*-{3-[2-(1-pentylhexyl)-1*H*-imidazol-4-yl]phenyl}thiophene-2-carboximidamide;
- *N'*-{4-[2-(2-cyclohexylethyl)-1*H*-imidazol-4-yl]phenyl}thiophene-2-carboximidamide;
- 10 - *N'*-{3-[2-(cyclohexylmethyl)-1*H*-imidazol-4-yl]phenyl}thiophene-2-carboximidamide;
- *N'*-{3-[2-(3-cyclohexylpropyl)-1*H*-imidazol-4-yl]phenyl}thiophene-2-carboximidamide;
- *N'*-[3-(2-hexyl-1*H*-imidazol-4-yl)phenyl]thiophene-2-carboximidamide;
- 15 - *N*-{4-[2-(2-cyclohexylethyl)-1*H*-imidazol-4-yl]phenyl}-*N''*-nitroguanidine;
- *N'*-(4-{2-[(cycloheptylamino)methyl]-1*H*-imidazol-4-yl}phenyl)thiophene-2-carboximidamide;
- *N'*-(4-{2-[(methylamino)methyl]-1*H*-imidazol-4-yl}phenyl)thiophene-2-carboximidamide;
- 20 - *N'*-(4-{2-[(cyclobutylamino)methyl]-1*H*-imidazol-4-yl}phenyl)thiophene-2-carboximidamide;
- *N'*-[4-(2-{[(2,2-diphenylethyl)amino]methyl}-1*H*-imidazol-4-yl)phenyl]thiophene-2-carboximidamide;
- *N'*-{3-[2-(2-{[(1*E*)-amino(thien-2-yl)methylene]amino}ethyl)-1*H*-imidazol-4-yl]phenyl}thiophene-2-carboximidamide;
- 25 - *N'*-(3-{2-[(phenylthio)methyl]-1*H*-imidazol-4-yl}phenyl)thiophene-2-carboximidamide;
- *N'*-(4-{2-[(phenylthio)methyl]-1*H*-imidazol-4-yl}phenyl)thiophene-2-carboximidamide;
- 30 - *N'*-{3-[2-(4-isobutylbenzyl)-1*H*-imidazol-4-yl]phenyl}thiophene-2-carboximidamide;

or a salt of said compound of general formula (I).

7. As a medicament, a compound of general formula (I) as defined in claim 1, or a pharmaceutically acceptable salt of said compound.
8. Pharmaceutical composition containing, as active ingredient, a compound of general formula (I) as defined in claim 1, or a pharmaceutically acceptable salt of said compound.
9. Use of a compound of general formula (I) as defined in claim 1, or a pharmaceutically acceptable salt of said compound, for preparing a medicament intended to treat or prevent a disorder/disease chosen from the following disorders/diseases: pain, multiple sclerosis, disorders of the central or peripheral nervous system, cardiovascular disorders, disorders of the skeletal muscle and of the neuromuscular joints, inflammatory diseases, hearing losses of traumatic, acoustic or toxic origin and tinnitus, complications linked with auto-immune and viral diseases and the neurological diseases associated with intoxication, treatments or disorders of genetic origin.
10. Use according to claim 9, characterized in that the medicament prepared is intended to treat or prevent pain.